NbN

🇺🇸 United States
inManage LTD  | 
28
ASO score
Text
21/100
Reviews
60/100
Graphic
28/100
Other
0/100
rating
App Rating
4.3
rating
Votes
10.9K
rating
App Age
11y 3m
rating
Last Update
Aug 30, 2024

Compare with Category Top Apps

Metrics
Current App
Category Top Average
Difference
Installs
38.8K
2.3M
-98%
Rating
4.31
4.16
+4%
Number of Ratings (Voted)
5.2K
2.5M
-100%
App Age
11y 2m
7y 8m
+45%
In-app Purchases Price
$0
$47
Update Frequency
485d
172d
+181%
Title Length
3
25
-88%
Short Description Length
37
63
-41%
Description Length
2 918
2 677
+9%
Number of Screenshots
440
1275
-65 %
Has Video?
No
0% has videos
Size
0MB
0MB

Category Ranking in United States

All
New
Trending Up
Trending Down
Top Dec 21, 2025 Dec 28, 2025
No results were found!
Top Dec 21, 2025 Dec 28, 2025
No results were found!
Top Dec 21, 2025 Dec 28, 2025
No results were found!
Top Dec 21, 2025 Dec 28, 2025
No results were found!

Downloads

Downloads Graph
Downloads icon
Total
38.6K
Last month icon
Last month
241

Text ASO

Title (
Characters: 3 of 50
)
NbN
Short Description (
Characters: 37 of 80
)
NbN - neuroscience based nomenclature
Description (
Characters: 2918 of 4000
)
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients. This practice is confusing. • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature. • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. • In this second edition 22 new medications were added so NbN includes now 130 medications. This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth. The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known. Therefore this nomenclature is based on: 1. The need to treat now. 2. Updated neuroscience insights. 3. The judgment of the members of the taskforce. Along these lines, we have come up with the following proposal: The Nomenclature: Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action. We also added 4 additional dimensions 4 Additional Dimensions: Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve" Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour. As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.}
Read more

Visual ASO

Screenshots

Rating & Reviews

Reviews Overview
🧐 Coming Soon…
Rating
4.3
10 895 voters

Some Latest Reviews

Jonas Amann
25 Sep, 2025
5
Useful tool for psychotropic medication, evidence based and up to date information.
Jonas Amann
10 Sep, 2025
1
App crashes when searching medication. Completely unusable at present. Unclear if still maintained - last update more than 1 year ago.
Snookie
12 Jul, 2024
3
It would be nice to use if it didn't crash when I start typing
Maria Luiza Mac-Allister
21 Jun, 2023
1
Instalei há pouco tempo porém o app vem apresentando instabilidade e fechando sozinho...
Bruno Mateu
19 Apr, 2021
1
Sin que funcione el buscador no se puede usar la app
P Awuzie
24 Feb, 2021
4
Alas some vital and forward thinking form medical people but this should be improved. A bit surprised that the medical professionals are finding app development challenging. Easy: Handover the development to technical people. Let's do this.
Beatriz BC
02 Feb, 2021
3
Antes funcionaba excelente pero de un tiempo para acá el buscador no funciona. Por favor verificarlo.
Carlos Cano
12 Jan, 2021
3
No funciona el buscador (antes si que funcionaba). Buena app
AHMED ELAGHOURY
25 Nov, 2020
5
[Nov 2020] UPDATE crashes the app. essential neuroscience info about psychotropics

Other

Additional Information
Rating:
4.26
Voted: 10.9K
Google Play Link:
Website:
Email:
Privacy Policy:
Categories: Medical
Size: -
Installs: 38.61K
App Age: 11 years 3 months
Release Date: Oct 14, 2014
Last Update: Aug 30, 2024
Version: 3.7
Version history
3.7
Aug 30, 2024
- Bug fixes.
3.5.6
Nov 12, 2023
Bug fixes.
Version history